Skip to main content
Clinical Trials/NCT05842811
NCT05842811
Not yet recruiting
Not Applicable

An Observational Study of Patients With Metabolic Syndrome and Related Conditions

Target PharmaSolutions, Inc.0 sites2,000,000 target enrollmentMay 24, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Metabolic Syndrome
Sponsor
Target PharmaSolutions, Inc.
Enrollment
2000000
Primary Endpoint
To characterize the natural history of disease in patients with metabolic syndrome and related conditions
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

TARGET-METABOLIC is an observational research study to conduct a comprehensive review of outcomes for patients with metabolic syndrome and related conditions.

Registry
clinicaltrials.gov
Start Date
May 24, 2023
End Date
December 31, 2038
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult patients at the time of enrollment with a diagnosis of metabolic syndrome or related conditions by ICD-10 code or with clinically calculated BMI ≥ 30 in the EHR/health system interface

Exclusion Criteria

  • Manual removal (sponsor or site request)
  • No EHR interface encounter \> 3 years
  • Engaged Cohort
  • Inclusion Criteria:
  • Adult patients diagnosed and managed for these conditions invited to participate
  • Ability to provide written informed consent
  • Exclusion Criteria:
  • Patient expressed desire to withdraw consent to complete PROs
  • Failure to complete PROs within 24 weeks of initial invitation
  • Greater than 24 months lapse of survey completion after baseline surveys completed

Outcomes

Primary Outcomes

To characterize the natural history of disease in patients with metabolic syndrome and related conditions

Time Frame: 15 Years

A detailed analysis of available demographics, anthropometric characteristics, glycemic metrics, medications, co-morbidities, and medical history from sites across the US will inform the profile for various patient populations enrolled into the study. Collection of detailed medical records will be curated and analyzed to characterize disease natural history, clinical course of disease, number and types of interventions, current treatment paradigms, and the patient diagnostic journey. These data may also establish incidence rates of events of special interest. Collection of prospective medical records for each patient enables the continuation of these analyses longitudinally for changes and progression to characterize the clinical course of disease. The progression of pre-existing co-morbidities and variances across populations will also be evaluated.

To assess safety and effectiveness of treatments for metabolic syndrome and related conditions.

Time Frame: 15 Years

The study will evaluate the characteristics of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for metabolic syndrome and related conditions. Treatments may be pharmacologic, surgical, procedures, radiologic or other interventions given to change the disease course/outcomes. Interval disease and medical events may vary depending on the patient's stage and type of disease and extent of co-morbidities at study entry and time of diagnosis.

Secondary Outcomes

  • To evaluate provider management practices in the treatment of patients with metabolic syndrome and related conditions(15 Years)
  • To evaluate longitudinal and patient reported outcomes in patients with metabolic syndrome and related conditions(15 Years)
  • To select and evaluate quality of care measures for patients with metabolic syndrome and related conditions(15 Years)

Similar Trials